Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement aims to evaluate the safety and pharmacokinetics of Lucid-21-302, a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action for the treatment of multiple sclerosis.
Lead Product(s): Lucid-21-302
Therapeutic Area: Neurology Product Name: Lucid-21-302
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: iNGENu
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 27, 2024
Details:
Lucid-MS (lucid-21-302) is a first-in-class neuroprotective compound with a novel mechanism of action which, in preclinical models, has shown to prevent myelin degradation (demyelination), a cause for MS and other neurodegenerative diseases.
Lead Product(s): Lucid-21-302
Therapeutic Area: Neurology Product Name: Lucid-MS
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
Lucid-MS (lucid-21-302) is a patented first-in-class, small molecule inhibitor of hypercitrullination, New Chemical Entity and a neuroprotective compound with a novel mechanism of action for the treatment of Multiple Sclerosis.
Lead Product(s): Lucid-21-302
Therapeutic Area: Neurology Product Name: Lucid-MS
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2023
Details:
Lucid-MS (lucid-21-302) is a first-in-class neuroprotective compound with a novel mechanism action which, in preclinical models, has shown to prevent myelin degradation (demyelination), a cause for MS and other neurodegenerative diseases.
Lead Product(s): Lucid-21-302
Therapeutic Area: Neurology Product Name: Lucid-MS
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 17, 2023
Details:
Lucid-201 is a psychedelic drug candidate targeting mental health disorders, and it is also investigating certain cannabinoids. FSD Pharma has established an Australian subsidiary to facilitate its development of Lucid-Psych and potentially other assets.
Lead Product(s): Lucid-Psych
Therapeutic Area: Psychiatry/Psychology Product Name: Lucid-201
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2023
Details:
Substance misuse is one of the most pervasive challenges around the globe, keeping this it in mind, company has announced the launch of a new research and development program focused on unmet medical needs for alcohol misuse disorder.
Lead Product(s): Undisclosed
Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
Lucid-MS (lucid-21-302) is a first-in-class neuroprotective compound with a novel mechanism action which, in preclinical models, has shown to prevent myelin degradation (demyelination), a cause for MS and other neurodegenerative diseases.
Lead Product(s): LUCID-21-302
Therapeutic Area: Neurology Product Name: Lucid-MS
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 07, 2023
Details:
FSD201 (palmitoylethanolamide) with enhanced anti-inflammatory properties, it is a fatty acid amide currently used as a dietary supplement, by increasing its bioavailability and efficacy making it suitable to treat a range of inflammatory conditions
Lead Product(s): Palmitoylethanolamide
Therapeutic Area: Musculoskeletal Product Name: FSD201
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Details:
Lucid-MS (lucid-21-302) is a first-in-class neuroprotective compound with a novel mechanism action which, in preclinical models, has shown to prevent myelin degradation (demyelination), a cause for MS and other neurodegenerative diseases.
Lead Product(s): Lucid-21-302
Therapeutic Area: Neurology Product Name: Lucid-MS
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
Lucid-201 is a psychedelic drug candidate targeting mental health disorders, and it is also investigating certain cannabinoids. FSD Pharma has established an Australian subsidiary to facilitate its development of Lucid-Psych and potentially other assets.
Lead Product(s): Lucid-Psych
Therapeutic Area: Psychiatry/Psychology Product Name: Lucid-201
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023